表达性帮助在造血干细胞移植血液肿瘤患者中的疗效:WISE随机对照试验方案
WISE研究是一项多中心双臂随机对照优效性试验,旨在评估表达性帮助(情绪表达写作与同伴支持写作)在成人血液肿瘤患者造血干细胞移植期间及移植后早期应用的效果。受试者在住院后移植前随机分组,完成四次简短写作,主要结局为症状负担,次要结局包括困扰、健康相关生活质量和疲乏,随访至干预后一年。
要点
- 表达性帮助是低负担简短心理干预,含情绪表达写作和同伴支持写作两个成分。
- WISE试验在移植期间及移植后早期症状高峰阶段干预,可能预防持续性症状。
- 主要结局为症状负担,次要结局为困扰、健康相关生活质量和疲乏。
核心结论
- WISE试验将严格评估表达性帮助在移植期间及移植后早期减少症状的疗效。
研究设计与样本
- 多中心双臂随机对照优效性试验,纳入计划接受造血干细胞移植的成人血液肿瘤患者。
主要发现
- 既往随机对照试验显示表达性帮助可减少长期移植幸存者的躯体症状和困扰。
关键数值与推荐
- 表达性帮助和中性写作均包含四次简短写作,从随机化后开始至出院后约4周结束。
- 症状负担为主要结局,困扰、健康相关生活质量和疲乏为次要结局。
- 在基线和干预后一年内医学相关时间点共进行七次评估。
临床怎么用
- 若证实有效,表达性帮助可作为移植期间及移植后早期可及的低负担心理干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: During, shortly after, and sometimes for years after hematopoietic stem cell transplant, a large proportion of hematological cancer patients undergoing transplant report significant physical and psychological symptoms and reduced health-related quality of life. To address these survivorship problems, we developed a low-burden, brief psychological intervention called expressive helping that includes two theory- and evidence-based components designed to work together synergistically: emotionally expressive writing and peer support writing. Building on evidence from a prior randomized control trial showing reductions in physical symptoms and distress in long-term transplant survivors with persistent survivorship problems, the Writing for Insight, Strength, and Ease (WISE) trial will evaluate the efficacy of expressive helping when used during transplant and in the early post-transplant period, when symptoms peak, and when intervention could prevent development of persistent symptoms. METHODS: WISE is a multi-site, two-arm randomized controlled efficacy trial. Adult hematological cancer patients scheduled for a hematopoietic stem cell transplant will complete baseline measures and then, after hospitalization but prior to transplant, they will be randomized to complete either expressive helping or a time and attention "neutral writing" task. Both expressive helping and neutral writing involve four brief writing sessions, beginning immediately after randomization and ending approximately 4 weeks after hospital discharge. Measures of symptom burden (primary outcome), distress, health-related quality of life, and fatigue (secondary outcomes) will be administered in seven assessments coinciding with medically relevant time points from baseline and to a year post-intervention. DISCUSSION: The steady and continuing increase in use of stem cell transplantation has created growing need for efficacious, accessible interventions to reduce the short- and long-term negative physical and psychosocial effects of this challenging but potentially life-saving treatment. Expressive helping is a psychological intervention that was designed to fill this gap. It has been shown to be efficacious in long-term transplant survivors but could have even greater impact if it is capable of reducing symptoms during and soon after transplant. The WISE study will evaluate these benefits in a rigorous randomized controlled trial. TRIAL REGISTRATION: Clinicaltrial.gov NCT03800758 . Registered January 11, 2019.
引用
- Whitmore L, Schulte T, Bovbjerg K, et al. Efficacy of expressive helping in adult hematologic cancer patients undergoing stem cell transplant: protocol for the Writing for Insight, Strength, and Ease (WISE) study's two-arm randomized controlled trial. Trials. 2021. PMID: 34670600. doi:10.1186/s13063-021-05676-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。